Fractyl Health Receives Clinical Trial Application Authorization In Netherlands To Initiate Phase 1/2 First-in-human Study Of RJVA-001, Expects To Start Dosing And Report Preliminary Data In 2H of 2026
Authorization advances Fractyl Health to a dual clinical-stage company, with Revita in pivotal development for post-GLP-1 weight maintenance and Rejuva entering first-in-human studies for type 2 diabetes
First-in-human dosing and preliminary data expected in the second half of 2026, subject to site activation
Rejuva clinical development funded within existing cash runway into early 2027, beyond anticipated REMAIN-1 Pivotal data readout; no change to capital plans
Login to comment